References

diaendo

Сахарный диабет

Diabetes mellitus

2072-03512072-0378

Endocrinology research centre

10.14341/2072-0351-6054

diaendo-6054

Research Article

Статьи

Articles

Сердечно-сосудистые последствия современного алгоритма сахароснижающей терапии: флорентийская гипотеза?

Cardiovascular implications of modern algorithm of hypoglycemic therapy: ?Florentine hypothesis?

Александров

Андрей Алексеевич

Aleksandrov

Andrey Alexeevich

endocar@mail.ru

Кухаренко

Светлана Семеновна

Kukharenko

Svetlana Semenovna

Ядрихинская

Мария Николаевна

Yadrikhinskaya

Maria Nikolaevna

ФГУ Эндокринологический научный центр, МоскваEndocrinology Research Centre, Moscow

2010

15122010

134

№4 (2010)

3037

2010

Александров А.А., Кухаренко С.С., Ядрихинская М.Н.

Aleksandrov A.A., Kukharenko S.S., Yadrikhinskaya M.N.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.dia-endojournals.ru/jour/article/view/6054

Внедрение современного алгоритма применения сахароснижающих средств у больных сахарным диабетом 2 типа направлено на эффек-тивное достижение целевых? уровней глюкозы и гликированного гемоглобина крови, ассоциирующихся с наименьшей сердечно-сосудистойсмертностью у этих больных.Наиболее часто применяемый тип комбинированной пероральной терапии - метформин + препараты сульфонилмочевины - позво-ляет достичь целевых? уровней углеводного обмена у большинства больных сахарным диабетом 2 типа. Однако оценка специфиче-ской сердечно-сосудистой эффективности данной терапии остается противоречивой. На основании эпидемиологическихматериалов в работе произведен анализ подобного рода вмешательств и выявлены наиболее безопасные типы подобного рода ком-бинированной терапии.

The modern algorithm of hypoglycemic therapy for patients with type 2 diabetes mellitus (DM2) has been designed to effectively reach the ?target?blood glucose and HbA1c levels associated with the lowest mortality rate.The most popular scheme is combined treatment with metformin andsulfonylureasthatmakes possible the achievement of the ?target? metabolic indices in the majority of DM2 patients. However, specific cardiovascular efficiency ofthis therapy is a matter of controversy. The safest modalities of combined therapy are discussed based on the analysis of relevant epidemiological data.

сахарный диабет 2 типаалгоритм сахароснижающей терапиисердечно-сосудистые осложнения

type 2 diabetes mellitusalgorithm of hypoglycemic therapycardiovascular complications

References1

Hamby R., Sherman L., Mehta J., Aintabian A. Reappraisal of the role of the diabetic state in coronary artery disease // Chest. - 1976. - Vol. 70. - Р. 251-257.

The DCCT Trial: The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus // N. Engl. J. Med. - 1993. - Vol. 329. - Р. 977-986.

Nathan D.M., Buse J.B., Davidson M.B., et al. Medical Management of Hyperglycemia in Type 2 Diabetes: a Consensus Algorithm for the Initiation and Adjustment of Therapy // Diabetes Care. - 2009. - Vol. 32 (1). - Р. 193-203.

Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой, 4-й вып. - М., 2009. - 114 с.

Сonsensus Statement:The pharmacological treatment of hyperglycemia in NIDDM // Diabetes Care. - 1996. - Vol. 19 [Suppl I]. - P. S54-S61.

Hermann L.S., Schersten B., Bitzen P.O., Kjellstrom T., Lindegarde F., Melander A. Therapeutic comparison of metformin and sulfonylurea< alone and in various combinations. A double-blind controlled study // Diabetes Care. - 1994. - Vol. 10. - Р. 1100-1109.

Hermann L.S., Schersten B., Melander A. Antihyperglycaemic efficacy, response prediction and dose- response relations of treatment with metformin and sulphonylurea, alone and in primary combination // Diab. Met. - 1994. - Vol. 10. - Р. 953-960.

DeFronzo R.A., Goodman A.M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The multicenter metformin study group // N. Engl. J. Med. - 1995. - Vol. 333. - Р. 541-549.

Garber A.J., Donovan Jr., D.S., Bruce S., Park J.S. Efficacy of glybu ri - de/metformin tablets compared with initial monotherapy in type 2 diabetes // J. Clin. Endocrinol. Metab. - 2003. - Vol. 88. - Р. 3598-3604.

Nathan D.M. Some answers, more controversy, from UKPDS // Lancet. - 1998. - Vol. 352. - Р. 832-833.

UK Perspective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complication in overweigth patients with type 2 diabetes (UKPDS 34) // Lancet. - 1998. - Vol. 352(9131). - Р. 854-865.

Fisman E.Z., Tenenbaum A., Boyko V. et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined gliburid/metformin therapy over a 7.7-year follow-up // Clin. Cardiol. - 2001. - Vol. 24(2). - Р. 151-158.

Mannucci E., Monami M., Masotti G., Marchionni N. All-cause mortality in diabetic patients treated with combination of sulfonylureas and biguanides // Diabetes. Metab. Res. Rev. - 2004. - Vol. 20(1). - Р. 44-47.

Olsson J., Lindberg G., Gottsater M. et al. Increased mortality in type 2 diabetic patients using sulfonylurea and metformin in combination: a population- based observational study // Diabetologia. - 2000. - Vol. 43(5). - Р. 558-560.

Bruno G., Merletti F., Boffetta P., et al. Impact of glycaemic control, hypertension and insulin treatment on general and cause-specific mortality: an Italian population-based cohort of type II [non-insulin-dependent] diabetes mellitus // Diabetologia. - 1999. - Vol. 42. - Р. 297-301.

Gulliford M., Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulfonylurea drugs in combination: cohord study // Diabetes Metab. Res. Rev. - 2004. - Vol. 20[3]. - Р. 239-245.

Johnson J.A., Simpson S.H., Toth E.L., Majumdar S.R. Redused cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes // Diabet. Med. - 2005. - Vol. 22 (4). - Р. 497-502.

Monami M., Luzzi C., Chiasserini V., Lamanna C., Chiasserini V., Addante F.,Desideri C.M., Massti G.,Marchionni N.,Mannucci Edorado Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin // Diabetes Metab. Res. Rev. - 2006. - Vol. 22. - Р. 477-482.

Blackburn H. Classification of the electrocardiogram for population studies: Minnesota // Code. J. Electrocardiol. - 1969. - Vol. 2. - Р. 305-310.

Charlson M., Szatrowski T., Peterson J., Gold J. Validation of a combined comorbidity index // J. Clin. Epidemiol. - 1994. - Vol. 47. - Р. 1245-1251.

Duncker D.J., van Zon N.S., Altman J.D., Pavek D.J., Bache R.J., Bache R.J. Role of K+ATP channels in coronary vasodilation during exercise // Ciirculation. - 1993. - Vol. 88. - Р. 1245-1253.

Cole W.C., McPherson C.D., Sontag D. ATP-regulated K+channels protect the myocardium against ischemia/reperfusion damage // Cir. Res. - 1991. - Vol. 69. - Р. 571-581.

Toombs C.F., McGee D.S., Johnston W.E., Vinten-Johansen J. Myocardial protective effects of adenosine. Infarct size reduction with pretreatment and continued receptor stimulation during ischemia // Circulation. - 1992. - Vol. 86. - Р. 986-994.

Pogatsa G., Koltai Z.M., Ballagi-Pordany G. Influence of hypoglycemic sulfonylurea compounds on the incidence of ventricular ectopic beats in non-insulin-dependent diabetic patiens treated with digitalis // Curr. Ther. Res. - 1993. - Vol. 53. - Р. 329-339.

Gover G.J., Sleph P.G., Dzwonick B.S. Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interactions with adenosine AI-receptors // Circulation. - 1992. - Vol. 86. - Р. 1310-1316.

Garratt K.N., Brady P.A., Hassinger N.L., Grill D.E., Terzic A., Holmes D.R. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for myocardial infarction // J. Am. Coll. Cardiol. - 1999. - Vol. 33. - Р. 119-124.

Jollis J.G., Simpson R.J., Cascio W.E., Chowdhury M.K., Crouse J.R., Smith S.C. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction // Am. Heart. J. - 1999. - Vol. 138. - P. S376-S380.

Klepzig H., Kober G., Matter C., Luus H., Schneider H., Boedeker K.H., Kiowski W., Amann F.H., Gruber D., Harris S., Burger W. Sulfonylureas and ischemic preconditioning. A doubl-blind, placebo-controlled evalution of glimepiride and glibenclamide // Eur. Heart. J. - 1999. - Vol. 20. - Р. 439-446.

Nagashima K. et al. Sulfonylurea and non - sulfonylurea hypoglycemic agents: pharmacological properties and tissue selectivity // Diabetes Research and Clinical Practice. - 2004. - P. S75-78.

Ovunc K. Effects of glibenclamide, a K[ATP] channel blocker, on warmup phenomenon in type 2 diabetic patients with chronic stable angina pectoris // Clin. Cardiol. - 2000. - Vol. 23[7]. - Р. 535-539.

Ming Wei et al. Low Fasting Plasma Glucose Level as a Predictor of Cardiovascular Disease and All-Cause Mortality // Circulation. - 2000. - Vol. 101. - Р. 2047-2052.

Marre M., Howlett H., Lehert P. and T. Allavoine. Improved glycaemic control with metformin-glibenclamide combined tablet therapy [Glucovance ®] in Type 2 diabetic patients inadequately controlled on metformin // Diabet. Med. - 2002. - Vol. 19. - Р. 673-680.

Charpentier G., Fleury F., Kabir M., Vaur L. and Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients // Diabet. Med. - 2001. - Vol. 16. - Р. 828-834.

Moses R., Slobodniuk R., Boyages S., Colagiuri S., Kidson W., Carter J., Donnelly T., Moffitt P., and Hopkins H. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes // Diabetes Care. - 1999. - Vol. 22. - Р. 119-124.

Adams J.F., Clark L.S., Ireland J.T., Kesson C.M., Watson W.S. Malabsorption of vitamin B12 and intrinsic factor secretion during biguanide therapy // Diabetologia. - 1982. - Vol. 24. - Р. 16-18.

Mayer E.L., Jacobsen D.W., Robinson K. Homocystein and coronary atherosclerosis // J. Am. Coll. Cardiol. - 1996. - 27. - Р. 517-527.

Nygard O., Nordrehaug L.E., Refsum H., Ueland P.M., Farstad M., Vollset S.E. Plasma homocystein levels and mortality in patients with coronary artery disease // N. Engl. J. Med. - 1997. - Vol. 337. - Р. 230-236.

Innerfield R.J. Metformin-associated mortality in U.S. studies // N. Engl. J. Med. - 1996. - Vol. 334. - Р. 1611-1613.

Fisman E.Z., Tenenbaum A., Benderly M., Goldbourt U., Behar S., Motro M. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year followup // Cardiology. - 1999. - Vol. 91. - Р. 195-202.

Goldner M.G., Knatterud G.L., Prout T.E. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. III Clinical implication of UGPDS results // J. Am. Med. Assoc. - 1971. - Vol. 218. - Р. 1400-1410.

Seltzer H.S. A summary of criticisms of the Findings and conclusions of the university group program [UGDP] // Diabetes. - 1972. - Vol. 21. - Р. 976-979.

Fisman E.Z., Tenenbaum A. F cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease // Cardiovascular Diabetology. - 2009. - Vol. 8. - Р. 38-51.

The authors declare that there are no conflicts of interest present.